Search
On January 13 (local time), Illumina unveiled its inaugural data product, the “Billion Cell Atlas,” crafted by its newly established business unit, BioInsight. This offering marks the first milestone in a three-year initiative to develop the “Fifty Billion Cell Atlas.” The atlas is set to produce single-cell transcriptomic data at an annual rate of 20 petabytes. Presently, Illumina has forged a partnership with pioneers like AstraZeneca, Merck & Co., and Eli Lilly and Company to commence the atlas's construction for a carefully selected set of cell lines. The objective is to propel drug target validation forward, facilitate large-scale training of sophisticated AI models, and enhance the understanding of the underlying mechanisms of diseases.
-
C114 Communication Network -
Communication Home
